EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial

Takashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe und 19 weitere

Breast Cancer · 2026

DOI: 10.1007/s12282-026-01865-0 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Breast Cancer, 2026. Verfasst von Takashi Yamanaka und 30 weiteren Autor:innen. Beteiligte Einrichtung: Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Tamoxifen, Pyridines, Piperazines. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In the Asian international PATHWAY trial, palbociclib-tamoxifen demonstrated improved progression-free survival compared with placebo-tamoxifen in patients with HR+/HER2- locally advanced or metastatic breast cancer (ABC). This analysis compared quality of life (QoL) between treatment arms. METHODS: Pre/peri or postmenopausal women with HR+/HER2- ABC were randomly assigned 1:1 to receive palbociclib-tamoxifen or placebo-tamoxifen. Patient-reported outcomes were assessed on day 1 of cycles 1 (baseline), 4, and 7, and at the end of treatment (EOT) using the EORTC QLQ-C30 and QLQ-BR23 questionnaires. Least-square mean (LSM) changes in scores from baseline were calculated. Kaplan-Meier method was used to calculate time to deterioration (TTD) in the minimally important difference (MID) in the pain subscale. RESULTS: In the comparison between treatment arms, no significant differences were observed in LSM changes in scores from baseline in global QoL (cycle 4: 0.70 [95% confidence interval (CI): -5.00, 6.41]; cycle 7: 2.17 [95% CI: -4.14, 8.48]; EOT: -5.19 [95% CI: -11.64, 1.26]). For both the EORTC QLQ-C30 and QLQ-BR23 functional and symptom subscales, no clinically meaningful differences between treatment arms were found in the LSM changes in scores from baseline. Median TTD in the MID in the pain subscale was 32.5 months (95% CI: 11.7, not estimable) for the palbociclib-tamoxifen arm and 21.2 months (95% CI: 5.5, 43.5) for the placebo-tamoxifen arm (hazard ratio = 0.729 [95% CI: 0.467, 1.138]). CONCLUSIONS: The combination of palbociclib and tamoxifen delayed deterioration in patients' QoL while they experienced reduced risk for disease progression. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03423199; study registration date: February 6, 2018.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTamoxifenPyridinesPiperazinesQuality of LifeAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleErb-b2 Receptor Tyrosine KinasesMiddle AgedDouble-Blind MethodAgedReceptors, EstrogenAdultReceptors, Progesterone

Stichwörter der Autor:innen

HR+/HER2−locally advanced or metastatic breast cancerpalbociclibpatient-reported outcomestamoxifen

Substanzen

palbociclibTamoxifenPyridinesPiperazinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenERBB2 protein, humanReceptors, Progesterone

Autor:innen und Institutionen

  • Kanagawa Cancer Center, Yokohama, Japan.
  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • National Cancer Center Hospital, Tokyo, Japan.
  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Chiba Cancer Center, Chiba, Japan.
  • Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.

Förderung

  • Pfizer Inc.

Zitieren

APA

Yamanaka, T., Sohn, J., Sudo, K., Mukai, H., Yamamoto, N., Chung, C. F., Lu, Y. S., Lee, K. H., Lee, S. C., Iwasa, T., Iwata, H., Watanabe, K., Jung, K. H., Tanabe, Y., Kang, S. Y., Yasojima, H., Aogi, K., Tokunaga, E., Sim, S. H., …, & Yonemori, K. (2026). Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial. Breast Cancer. https://doi.org/10.1007/s12282-026-01865-0

Vancouver

Yamanaka T, Sohn J, Sudo K, Mukai H, Yamamoto N, Chung CF, et al. Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial. Breast Cancer. 2026. doi:10.1007/s12282-026-01865-0

BibTeX
@article{Yamanaka2026,
  author = {Yamanaka, Takashi and Sohn, Joohyuk and Sudo, Kazuki and Mukai, Hirofumi and Yamamoto, Naohito and Chung, Chi-Feng and Lu, Yen-Shen and Lee, Kyung-Hun and Lee, Soo-Chin and Iwasa, Tsutomu and Iwata, Hiroji and Watanabe, Kenichi and Jung, Kyung Hae and Tanabe, Yuko and Kang, Seok Yun and Yasojima, Hiroyuki and Aogi, Kenjiro and Tokunaga, Eriko and Sim, Sung Hoon and Yap, Yoon Sim and Matsumoto, Koji and Tseng, Ling-Ming and Umeyama, Yoshiko and Noguchi, Emi and Hata, Tomomi and Kuchiba, Aya and Shibata, Taro and Nakamura, Kenichi and Fujiwara, Yasuhiro and Tamura, Kenji and Yonemori, Kan},
  title = {Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial},
  journal = {Breast Cancer},
  year = {2026},
  doi = {10.1007/s12282-026-01865-0}
}
Kostenlos starten →